Core Viewpoint - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response about its financial performance and customer relationships [1][2]. Financial Performance - The company achieved a revenue of 1.299 billion RMB in 2024, representing a year-on-year growth of 21.78%. The overseas business contributed 784 million RMB, accounting for 60.35% of total revenue [2][3]. - The gross profit margin for overseas business was 25.44%, which is 4.81 percentage points higher than that of domestic business [2][3]. Customer Information - The company provided detailed information on major customers, including transaction amounts and accounts receivable balances for both domestic and overseas clients [3][4]. - The top overseas customer generated sales of 132.93 million RMB in 2024, while the top domestic customer generated sales of 66.34 million RMB [3][4]. Gross Margin Analysis - The difference in gross margins between overseas and domestic sales is attributed to the product mix and pricing strategies. The overseas sales model allows for higher pricing due to the demand for premium products [8][9]. - The gross margin for oral care products overseas is 7.83 percentage points higher than that of domestic sales, while for wet wipes, the difference is 11.4 percentage points [8][9]. Revenue Growth Drivers - The revenue growth is driven by increased customer demand, new product development, and the expansion of sales channels, including the acquisition of Shen'enkang, which contributed to the overall revenue increase [13][14]. - The main categories contributing to revenue growth include oral care products, wet wipes, and probiotics, with oral care products alone generating 843.15 million RMB in 2024, up 16.80% from the previous year [13][14]. Acquisition and Goodwill Impairment - The company acquired 52% of Shen'enkang, which resulted in a goodwill of 91.01 million RMB. However, Shen'enkang did not meet its performance commitments in 2024, leading to a goodwill impairment of 39.62 million RMB [14][15].
倍加洁: 倍加洁集团股份有限公司关于2024年年度报告信息披露监管问询函的回复公告